<?xml version="1.0" encoding="UTF-8"?>
<ref id="B45-molecules-25-02529">
 <label>45.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lawitz</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Sulkowski</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Jacobson</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Kraft</surname>
    <given-names>W.K.</given-names>
   </name>
   <name>
    <surname>Maliakkal</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Al-Ibrahim</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Gordon</surname>
    <given-names>S.C.</given-names>
   </name>
   <name>
    <surname>Kwo</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Rockstroh</surname>
    <given-names>J.K.</given-names>
   </name>
   <name>
    <surname>Panorchan</surname>
    <given-names>P.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Characterization of Vaniprevir, a Hepatitis C Virus NS3/4A Protease Inhibitor, in Patients With HCV Genotype 1 Infection: Safety, Antiviral Activity, Resistance, and Pharmacokinetics</article-title>
  <source>Antivir. Res.</source>
  <year>2013</year>
  <volume>99</volume>
  <fpage>214</fpage>
  <lpage>220</lpage>
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.05.015</pub-id>
  <pub-id pub-id-type="pmid">23747481</pub-id>
 </element-citation>
</ref>
